The global contract development and manufacturing organisation (CDMO) industry is witnessing a significant shift as multinational pharmaceutical companies increasingly diversify their manufacturing footprint away from China. With regulatory scrutiny intensifying around Chinese CDMO giant WuXi AppTec, Indian players are emerging as trusted alternatives for global drugmakers.
Speaking to ET Now, Sivaramakrishnan Chittor, CFO of Sai Life Sciences, said the ongoing supply-chain realignment presents a landmark opportunity for India's CDMO sector, although the benefits are expected to materialise gradually given the regulatory nature of pharmaceutical manufacturing.
